Bio-Rad Laboratories, Inc. (BIO.B)

Market Cap	10.16B
Revenue (ttm)	2.58B
Net Income (ttm)	-778.69M
Shares Out	28.00M
EPS (ttm)	-27.41
PE Ratio	n/a
Forward PE	31.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81
Open	334.85
Previous Close	334.85
Day's Range	334.85 - 334.85
52-Week Range	294.23 - 341.40
Beta	0.95
Analysts	Strong Buy
Price Target	411.00 (+22.74%)
Earnings Date	Oct 30, 2024

About BIO.B

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety mar...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 8,030
• Stock Exchange: NYSE
• Ticker Symbol: BIO.B
• Website: https://www.bio-rad.com

Financial Performance

In 2023, Bio-Rad Laboratories's revenue was $2.67 billion, a decrease of -4.67% compared to the previous year's $2.80 billion. Losses were -$637.32 million, -82.43% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for BIO.B stock is "Strong Buy." The 12-month stock price forecast is $411.0, which is an increase of 22.74% from the latest price.

Price Target

$411.0

(22.74% upside)

Analyst Consensus: Strong Buy